Literature DB >> 35067828

Negative symptoms in Huntington's disease.

Paola Soliveri1,2, Dominga Paridi3,4, Francesca Del Sorbo3,5, Irene Tramacere6, Floriano Girotti3,7.   

Abstract

BACKGROUND: Apathy is the commonest psychiatric manifestation in Huntington's disease (HD). We investigated negative psychiatric symptoms-as determined by the Scale for the Assessment of Negative Psychiatric Symptoms (SANS)-in early and intermediate HD patients, hypothesizing that such symptoms would be prominent and constitute a more comprehensive and clinically relevant assessment than apathy alone. We also assessed relations between negative symptoms and disease stage, mood, motor, and cognitive disturbances.
METHODS: Thirty-five stage 1 and twenty-nine stage 2 consecutive adult HD outpatients were administered SANS; the Scale for the Assessment of Positive Psychiatric Symptoms (SAPS); the motor section of the Unified Huntington's Disease Rating Scale (UHDRS); Total Functional Capacity (TFC); and instruments to assess cognition, anxiety, and depression.
RESULTS: The groups had similar age, education, and CAG length. Scores on the Hamilton depression and anxiety scales, and SAPS were similar. Negative symptoms were pervasive in the entire series. Illness duration, UHDRS, TFC, cognition, and SANS scores were significantly worse in stage 2. Mini Mental State Examination (MMSE) and SAPS scores were significantly (multiple regression) associated with SANS score, while Hamilton depression and UHDRS scores were not. SANS score was also associated with stage after removing the cognition-related domains of alogia and attention.
CONCLUSIONS: Negative symptoms are pervasive in HD but more severe in stage 2. The associations of SANS with MMSE and SAPS suggest impaired cognition and thinking as important in generating negative symptoms. SANS appears useful for revealing a wide range of negative symptoms in HD.
© 2021. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  Apathy; Huntington’s disease; Negative psychiatric symptoms; Positive psychiatric symptoms

Mesh:

Year:  2022        PMID: 35067828     DOI: 10.1007/s10072-021-05787-x

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  20 in total

1.  The NIMH-MATRICS consensus statement on negative symptoms.

Authors:  Brian Kirkpatrick; Wayne S Fenton; William T Carpenter; Stephen R Marder
Journal:  Schizophr Bull       Date:  2006-02-15       Impact factor: 9.306

2.  The current conceptualization of negative symptoms in schizophrenia.

Authors:  Stephen R Marder; Silvana Galderisi
Journal:  World Psychiatry       Date:  2017-02       Impact factor: 49.548

3.  Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease.

Authors:  Saul Martinez-Horta; Jesus Perez-Perez; Erik van Duijn; Ramon Fernandez-Bobadilla; Mar Carceller; Javier Pagonabarraga; Berta Pascual-Sedano; Antonia Campolongo; Jesus Ruiz-Idiago; Frederic Sampedro; G Bernhard Landwehrmeyer; Jaime Kulisevsky
Journal:  Parkinsonism Relat Disord       Date:  2016-02-11       Impact factor: 4.891

4.  Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group.

Authors:  P Robert; K L Lanctôt; L Agüera-Ortiz; P Aalten; F Bremond; M Defrancesco; C Hanon; R David; B Dubois; K Dujardin; M Husain; A König; R Levy; V Mantua; D Meulien; D Miller; H J Moebius; J Rasmussen; G Robert; M Ruthirakuhan; F Stella; J Yesavage; R Zeghari; V Manera
Journal:  Eur Psychiatry       Date:  2018-08-17       Impact factor: 5.361

Review 5.  Neurobiological background of negative symptoms.

Authors:  Silvana Galderisi; Eleonora Merlotti; Armida Mucci
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-03-24       Impact factor: 5.270

6.  Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders.

Authors:  P Robert; C U Onyike; A F G Leentjens; K Dujardin; P Aalten; S Starkstein; F R J Verhey; J Yessavage; J P Clement; D Drapier; F Bayle; M Benoit; P Boyer; P M Lorca; F Thibaut; S Gauthier; G Grossberg; B Vellas; J Byrne
Journal:  Eur Psychiatry       Date:  2009-02-07       Impact factor: 5.361

7.  Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY).

Authors:  Erik van Duijn; David Craufurd; Anna A M Hubers; Erik J Giltay; Raphael Bonelli; Hugh Rickards; Karen E Anderson; Marleen R van Walsem; Rose C van der Mast; Michael Orth; G Bernhard Landwehrmeyer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-05-14       Impact factor: 10.154

8.  Modeling the role of negative symptoms in determining social functioning in individuals at clinical high risk of psychosis.

Authors:  Danielle A Schlosser; Timothy R Campellone; Bruno Biagianti; Kevin L Delucchi; David E Gard; Daniel Fulford; Barbara K Stuart; Melissa Fisher; Rachel L Loewy; Sophia Vinogradov
Journal:  Schizophr Res       Date:  2015-10-31       Impact factor: 4.939

Review 9.  Clinical Features of Huntington's Disease.

Authors:  Rhia Ghosh; Sarah J Tabrizi
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

10.  Multidimensional Apathy: The Utility of the Dimensional Apathy Scale in Huntington's Disease.

Authors:  Kelly J Atkins; Sophie C Andrews; Trevor T-J Chong; Julie C Stout
Journal:  Mov Disord Clin Pract       Date:  2021-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.